WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326897
CAS#: 111686-79-4 (HCl)
Description: Remacemide, also known as PR-934423 and FPL 12924AA, is a low-affinity NMDA antagonist with sodium channel blocking properties. It has been studied for the treatment of acute ischemic stroke, epilepsy, Huntington's disease, and Parkinson's disease. Remacemide binds weakly and noncompetitively to the ionic channel site of the NMDA receptor complex. Remacemide binds both allosterically and in the channel. However, because remacemide binds so weakly to NMDAR, much of remacemide's in vivo effect against excitotoxicity is thought to be caused by its metabolic transformation to the more potent desglycine derivative FPL 12495.
Hodoodo Cat#: H326897
Name: Remacemide HCl
CAS#: 111686-79-4 (HCl)
Chemical Formula: C17H21ClN2O
Exact Mass: 0.00
Molecular Weight: 304.818
Elemental Analysis: C, 66.99; H, 6.94; Cl, 11.63; N, 9.19; O, 5.25
Related CAS #: 128298-28-2 (free base) 111686-79-4 (HCl)
Synonym: PR-934423; PR934423 PR 934423; PR 934-423A; FPL 12924AA; Remacemide hydrochloride
IUPAC/Chemical Name: 2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide monohydrochloride
InChi Key: HYQMIUSWZXGTCC-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H20N2O.ClH/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14;/h2-11H,12-13,18H2,1H3,(H,19,20);1H
SMILES Code: O=C(NC(C1=CC=CC=C1)(C)CC2=CC=CC=C2)CN.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 128298-28-2 (Remacemide) 111686-79-4 (Remacemide hydrochloride)
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 304.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Wesnes KA, Edgar C, Dean AD, Wroe SJ. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy Behav. 2009 Mar;14(3):522-8. doi: 10.1016/j.yebeh.2008.11.012. Epub 2008 Dec 25. PubMed PMID: 19111629.
2: Borowicz KK, Malek R, Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock. Epilepsy Behav. 2007 Aug;11(1):6-12. Epub 2007 Jun 29. PubMed PMID: 17602881.
3: Wright LK, Pearson EC, Hammond TG, Paule MG. Behavioral effects associated with chronic ketamine or remacemide exposure in rats. Neurotoxicol Teratol. 2007 May-Jun;29(3):348-59. Epub 2007 Jan 16. PubMed PMID: 17291718.
4: Małek R, Borowicz KK, Kimber-Trojnar Z, Sobieszek G, Piskorska B, Czuczwar SJ. Remacemide--a novel potential antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):691-8. Review. PubMed PMID: 14704464.
5: Calabresi P, Marti M, Picconi B, Saulle E, Costa C, Centonze D, Pisani F, Bernardi G. Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. Exp Neurol. 2003 Aug;182(2):461-9. PubMed PMID: 12895457.
6: Brodie MJ, Wroe SJ, Dean AD, Holdich TA, Whitehead J, Stevens JW. Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. Epilepsy Behav. 2002 Apr;3(2):140-146. PubMed PMID: 12609415.
7: Whitehead J, Stevens J, Brodie M, Wroe S, Dean A, Holdich T. Remacemide versus carbamazepine in newly diagnosed epilepsy. Epilepsy Behav. 2002 Aug;3(4):405-406. PubMed PMID: 12609343.
8: Nehlig A, Boehrer A. Effects of remacemide in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsy Res. 2003 Jan;52(3):253-61. PubMed PMID: 12536058.
9: Leach JP, Marson AG, Hutton JL. Remacemide for drug-resistant localization related epilepsy. Cochrane Database Syst Rev. 2002;(4):CD001900. Review. PubMed PMID: 12519561.
10: Devinsky O, Vazquez B, Faught E, Leppik IE, Pellock JM, Schachter S, Alderfer V, Holdich TA. A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment. Seizure. 2002 Sep;11(6):371-6. PubMed PMID: 12160664.
11: Sills GJ, Santangeli S, Forrest G, Brodie MJ. Influence of cytochrome P450 induction on the pharmacokinetics and pharmacodynamics of remacemide hydrochloride. Epilepsy Res. 2002 May;49(3):247-54. PubMed PMID: 12076846.
12: Chadwick DW, Betts TA, Boddie HG, Crawford PM, Lindstrom P, Newman PK, Soryal I, Wroe S, Holdich TA. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Seizure. 2002 Mar;11(2):114-23. PubMed PMID: 11945098.
13: Jones MW, Blume WT, Guberman A, Lee MA, Pillay N, Weaver DF, Veloso F, Holdich TA. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen. Seizure. 2002 Mar;11(2):104-13. PubMed PMID: 11945097.
14: Popke EJ, Patton R, Newport GD, Rushing LG, Fogle CM, Allen RR, Pearson EC, Hammond TG, Paule MG. Assessing the potential toxicity of MK-801 and remacemide: chronic exposure in juvenile rhesus monkeys. Neurotoxicol Teratol. 2002 Mar-Apr;24(2):193-207. PubMed PMID: 11943507.
15: Santangeli S, Sills GJ, Thompson GG, Brodie MJ. Na(+) channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur J Pharmacol. 2002 Mar 1;438(1-2):63-8. PubMed PMID: 11906711.
16: Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002 Mar 1;22(5):1592-9. PubMed PMID: 11880489.
17: Santangeli S, Sills GJ, Stone TW, Brodie MJ. Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice. Neurosci Lett. 2002 Mar 15;321(1-2):33-6. PubMed PMID: 11872250.
18: Ramaekers G, Lamers J, Verhey F, Muntjewerff D, Mobbs E, Sanders N, Lewis M, Lockton A. A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic. Psychopharmacology (Berl). 2002 Jan;159(2):203-10. Epub 2001 Sep 22. PubMed PMID: 11862350.
19: Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001 Nov 27;315(3):149-53. PubMed PMID: 11716985.
20: Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol. 2001 Oct;58(10):1660-8. PubMed PMID: 11594926.